Data completeness
0/8 — Limited
Drug data last refreshed 39m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFADYL (cephapirin sodium) is an injectable first-generation cephalosporin antibiotic developed by Bristol Myers Squibb. It is indicated for bacterial infections susceptible to cephalosporin therapy, administered via injection for systemic treatment. The drug works by inhibiting bacterial cell wall synthesis, making it bactericidal against susceptible pathogens.
Pre-Launch
As a pre-launch product, the team is in development and planning phases; full commercial sizing and hiring will accelerate upon regulatory approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CEFADYL during pre-launch offers opportunity to build a brand from the ground up in a competitive injectable market, with roles spanning regulatory, commercial, and medical affairs. Career advancement will depend on successful market entry execution and capturing share in a mature, price-sensitive segment.
Brand ManagerMedical Science Liaison
Worked on CEFADYL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.